M C Dubinsky

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. pmc Special issues in pediatric inflammatory bowel disease
    Marla Dubinsky
    Pediatric IBD Center, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California Los Angeles, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    World J Gastroenterol 14:413-20. 2008
  2. ncbi request reprint 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease
    Marla C Dubinsky
    Division of Gastroenterology and Genetics, Department of Medicine and Pediatrics, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
    Gastroenterology 122:904-15. 2002
  3. pmc Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn's disease
    Marla C Dubinsky
    Departments of Pediatrics, Pediatric Inflammatory Bowel Disease Center and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Inflamm Bowel Dis 19:1662-70. 2013
  4. ncbi request reprint An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy
    M C Dubinsky
    Department of Medicine, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 7:181-9. 2001
  5. pmc IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease
    Marla C Dubinsky
    Department of Pediatrics, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Inflamm Bowel Dis 13:511-5. 2007
  6. ncbi request reprint Optimizing immunomodulator therapy for inflammatory bowel disease
    Marla C Dubinsky
    Pediatric IBD Center, Cedars Sinai Medical Center, 8635 West 3rd Street, Suite 1165W, Los Angeles, CA 90048, USA
    Curr Gastroenterol Rep 5:506-11. 2003
  7. ncbi request reprint 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients
    Marla C Dubinsky
    Pediatric Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, 8635 West Third Street, Suite 1165W, Los Angeles, California 90048, USA
    Gastroenterology 125:298-303. 2003
  8. doi request reprint What is the role of serological markers in IBD? Pediatric and adult data
    Marla Dubinsky
    Pediatric IBD Center, Cedars Sinai Medical Center, David Geffen School of Medicine, Los Angeles, CA 90048, USA
    Dig Dis 27:259-68. 2009
  9. pmc Increased immune reactivity predicts aggressive complicating Crohn's disease in children
    Marla C Dubinsky
    Department of Pediatrics, IBD Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 6:1105-11. 2008
  10. ncbi request reprint Differences in the management of Crohn's disease among experts and community providers, based on a national survey of sample case vignettes
    E Esrailian
    David Geffen School of Medicine at UCLA, Division of Digestive Diseases, Los Angeles, CA 90095, USA
    Aliment Pharmacol Ther 26:1005-18. 2007

Research Grants

Detail Information

Publications43

  1. pmc Special issues in pediatric inflammatory bowel disease
    Marla Dubinsky
    Pediatric IBD Center, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California Los Angeles, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    World J Gastroenterol 14:413-20. 2008
    ..This review highlights special considerations in the management of the child with IBD...
  2. ncbi request reprint 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease
    Marla C Dubinsky
    Division of Gastroenterology and Genetics, Department of Medicine and Pediatrics, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
    Gastroenterology 122:904-15. 2002
    ..The objectives of this study were to determine whether dose escalation optimizes both 6-TGN levels and efficacy in patients failing therapy because of subtherapeutic 6-TGN levels and its effect on TPMT...
  3. pmc Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn's disease
    Marla C Dubinsky
    Departments of Pediatrics, Pediatric Inflammatory Bowel Disease Center and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Inflamm Bowel Dis 19:1662-70. 2013
    ....
  4. ncbi request reprint An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy
    M C Dubinsky
    Department of Medicine, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 7:181-9. 2001
    ..This pilot study evaluated the safety, tolerance, and efficacy of 6-TG in the subgroup of Crohn's disease (CD) patients failing to attain adequate disease control with traditional 6-MP/AZA therapy...
  5. pmc IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease
    Marla C Dubinsky
    Department of Pediatrics, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Inflamm Bowel Dis 13:511-5. 2007
    ..It is unknown whether IL-23R is associated with IBD in children. The aim was to examine the association of IL-23R with susceptibility to IBD in pediatric patients...
  6. ncbi request reprint Optimizing immunomodulator therapy for inflammatory bowel disease
    Marla C Dubinsky
    Pediatric IBD Center, Cedars Sinai Medical Center, 8635 West 3rd Street, Suite 1165W, Los Angeles, CA 90048, USA
    Curr Gastroenterol Rep 5:506-11. 2003
    ....
  7. ncbi request reprint 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients
    Marla C Dubinsky
    Pediatric Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, 8635 West Third Street, Suite 1165W, Los Angeles, California 90048, USA
    Gastroenterology 125:298-303. 2003
    ..The aim of this study was to describe the association between 6-TG and NRH in IBD...
  8. doi request reprint What is the role of serological markers in IBD? Pediatric and adult data
    Marla Dubinsky
    Pediatric IBD Center, Cedars Sinai Medical Center, David Geffen School of Medicine, Los Angeles, CA 90048, USA
    Dig Dis 27:259-68. 2009
    ..This search, however, has taken a very exciting turn in the direction of finding biologic and genetic markers that can assess the natural history and predict the course of individual's disease including response to treatments over time...
  9. pmc Increased immune reactivity predicts aggressive complicating Crohn's disease in children
    Marla C Dubinsky
    Department of Pediatrics, IBD Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 6:1105-11. 2008
    ..The aims of this study were to determine whether immune responses and/or CARD15 variants are associated with complicated disease phenotypes and predict disease progression...
  10. ncbi request reprint Differences in the management of Crohn's disease among experts and community providers, based on a national survey of sample case vignettes
    E Esrailian
    David Geffen School of Medicine at UCLA, Division of Digestive Diseases, Los Angeles, CA 90095, USA
    Aliment Pharmacol Ther 26:1005-18. 2007
    ..When faced with the same set of facts, healthcare providers often make different diagnoses, employ different tests and prescribe disparate therapies...
  11. pmc MAGI2 genetic variation and inflammatory bowel disease
    Dermot P B McGovern
    Medical Genetics Institute and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 15:75-83. 2009
    ..Our aim was to test MAGI2 variants for association with IBD and also their role in determining intermediate hereditary phenotypes defined by antibody production to microbial antigens...
  12. doi request reprint Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease
    T Dassopoulos
    Department of Medicine, Johns Hopkins University, Baltimore, MD, USA
    Aliment Pharmacol Ther 39:163-75. 2014
    ..Azathioprine (AZA), a pro-drug metabolised to the active metabolites 6-tioguanine nucleotides (6TGN), is a steroid-sparing therapy for Crohn's disease (CD)...
  13. ncbi request reprint New patients: should children be treated differently?
    M C Dubinsky
    Pediatric IBD Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Colorectal Dis 8:15-9. 2006
    ..A recent case report, involving a 15-year old boy presenting with abdominal pain and bloody diarrhoea, illustrates the difficulty in correctly diagnosing IBD in children and the need for optimizing therapy to achieve treatment success...
  14. pmc Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis
    Gil Y Melmed
    Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Dis Colon Rectum 51:100-8. 2008
    ..Preoperative predictors for Crohn's disease post-ileal pouch-anal anastomosis have not been prospectively defined...
  15. pmc Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists
    Brennan M R Spiegel
    Veteran s Administration Greater Los Angeles Healthcare System, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 7:168-74, 174.e1. 2009
    ..We performed a national vignette survey to measure variations in decision-making in areas of controversy...
  16. doi request reprint A prospective evaluation of the long-term outcome of ileal pouch-anal anastomosis in patients with inflammatory bowel disease-unclassified and indeterminate colitis
    Zuri A Murrell
    Department of Surgery, Division of Colon and Rectal Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Dis Colon Rectum 52:872-8. 2009
    ..The aim of this study was to prospectively evaluate the long-term outcome of ileal pouch-anal anastomosis in a closely monitored cohort of patients with ulcerative colitis or indeterminate colitis...
  17. pmc Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis
    Phillip Fleshner
    Division of Colon and Rectal Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 6:561-8. 2008
    ..The aim of this study was to assess associations of preoperative perinuclear antineutrophil cytoplasmic antibody (pANCA) and anti-CBir1 flagellin on AP or CP development...
  18. ncbi request reprint Elevated platelet count before ileal pouch-anal anastomosis for ulcerative colitis is associated with the development of chronic pouchitis
    Aderet Okon
    Division of Colon and Rectal Surgery, Department of Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Am Surg 71:821-6. 2005
    ..03). The incidence of CP was significantly higher after IPAA in UC patients having thrombocytosis before surgery compared to UC patients having a normal platelet count before surgery...
  19. pmc Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease
    Dermot P B McGovern
    Inflammatory Bowel and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Hum Mol Genet 19:3468-76. 2010
    ..001). These findings strongly implicate this locus in CD susceptibility and highlight the role of the mucus layer in the development of CD...
  20. doi request reprint Management of the pregnant IBD patient
    Marla Dubinsky
    Department of Pediatrics, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 14:1736-50. 2008
    ..We would like to emphasize that the information presented here must be individualized to the specific situation of each patient, their acceptance of risk, and their degree of disease severity...
  21. pmc Genetic epistasis of IL23/IL17 pathway genes in Crohn's disease
    Dermot P B McGovern
    Medical Genetics Institute and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Inflamm Bowel Dis 15:883-9. 2009
    ..Genetic variants in the IL23R and IL12B have been associated with CD susceptibility. We investigated 10 genes within the IL23/IL17 pathway in a case-control study of 763 CD cases and 254 healthy controls...
  22. ncbi request reprint Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation
    Thomas Hui
    Division of Colon and Rectal Surgery, Cedars Sinai Medical Center, Los Angeles, California, USA
    Dis Colon Rectum 48:1254-62. 2005
    ..We examined whether preoperative serologic responses to these antigens were associated with Crohn's disease in indeterminate colitis patients after ileal pouch-anal anastomosis...
  23. ncbi request reprint A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis
    Phillip Fleshner
    Division of Colon and Rectal Surgery, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 5:952-8; quiz 887. 2007
    ..The aim of this study was to identify important clinical risk factors associated with AP or CP...
  24. ncbi request reprint Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis?
    Stefanie J Schluender
    Division of Colon and Rectal Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, 8737 Beverly Boulevard, Suite 101, Los Angeles, California 90048, USA
    Dis Colon Rectum 50:1747-53. 2007
    ..This study was designed to compare short-term complications in patients with ulcerative colitis who were treated with and without infliximab before colectomy...
  25. ncbi request reprint Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease
    William S Mow
    Inflammatory Bowel Disease Center, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 2:31-40. 2004
    ..The aim of this study is to assess the clinical utility of WCE in the evaluation of patients with known or suspected inflammatory bowel disease (IBD)...
  26. ncbi request reprint Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapy
    Sunita Shastri
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Arch Pathol Lab Med 128:49-53. 2004
    ..Recently, 6-thioguanine has been used to treat patients with inflammatory bowel disease who have been resistant to other forms of therapy...
  27. ncbi request reprint Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety
    Marla C Dubinsky
    Pediatric IBD Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Clin Gastroenterol Hepatol 2:731-43. 2004
    ..By gaining an understanding of the pharmacology and metabolism of thiopurine therapy and putting it into the clinical context, clinicians will be able to optimize thiopurine therapy in IBD...
  28. ncbi request reprint Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn
    Eric A Vasiliauskas
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Clin Gastroenterol Hepatol 4:1255-8. 2006
    ..As a result of heightened maternal concern triggered by recent labeling changes, infliximab levels were measured in the newborn of a mother treated with infliximab...
  29. ncbi request reprint Monitoring of AZA/6-MP treatment in children with IBD is necessary
    Marla C Dubinsky
    Pediatric Gastroenterology, Cedars Sinai Hospital, Los Angeles, CA 90048, USA
    Inflamm Bowel Dis 9:386-8; discussion 392-3. 2003
  30. ncbi request reprint Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine
    Marla C Dubinsky
    Department of Medicine, Division of Gastroenterology, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
    Am J Gastroenterol 98:1058-63. 2003
    ..The aim of this study was to determine if hypersensitivity reactions to 6-MP/AZA reoccur with 6-TG therapy...
  31. ncbi request reprint A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine
    Marla C Dubinsky
    Department of Pediatrics, Pediatric IBD Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Am J Gastroenterol 100:2239-47. 2005
    ..We performed a decision analysis to estimate the potential costs and effectiveness of TPMT screening and MM as disease management strategies for CD...
  32. ncbi request reprint Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America
    Athos Bousvaros
    J Pediatr Gastroenterol Nutr 44:653-74. 2007
    ....
  33. ncbi request reprint Suspected inflammatory bowel disease--the clinical and economic impact of competing diagnostic strategies
    Marla C Dubinsky
    Department of Pediatrics, Cedars Sinai Medical Center, University of California Los Angeles School of Medicine, USA
    Am J Gastroenterol 97:2333-42. 2002
    ....
  34. ncbi request reprint Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease
    Jacob Spivak
    Division of Colon and Rectal Surgery, Department of Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Inflamm Bowel Dis 12:1122-30. 2006
    ..This study examines the association between clinical features and seroreactivity to these microbial and auto-antigens in predicting a clinical response to fecal diversion...
  35. ncbi request reprint Clinical perspectives in Crohn's disease. Serologic and prognostic biomarkers: who, when, and how?
    Marla C Dubinsky
    Pediatric Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Rev Gastroenterol Disord 7:S3-7. 2007
    ..Determining the factors that can predict the progression from uncomplicated to complicated disease states may stratify patients into at-risk populations and have an impact on their ultimate therapeutic management...
  36. ncbi request reprint Challenges in pediatric inflammatory bowel disease
    Athos Bousvaros
    Children s Hospital Boston and Harvard Medical School, Boston, MA 02115, USA
    Inflamm Bowel Dis 12:885-913. 2006
    ..At the conclusion of the meeting, investigators discussed the formation of a multicenter collaborative network to advance clinical and basic research in the field...
  37. ncbi request reprint Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease
    Stephen A Geller
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Am J Surg Pathol 28:1204-11. 2004
    ..6-TG-related hepatotoxicity, including liver biochemistry value elevations, sinusoidal collagen deposition on electron microscopy, and veno-occlusive disease, have been described related to its use as therapy for neoplastic disease...
  38. doi request reprint Disease perceptions among people with Crohn's disease
    Sunanda V Kane
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 14:1097-101. 2008
    ..We sought to characterize CD patient perceptions of both overall disease course and current symptomatology based on an objective symptom scale and to explore the relationship between perceptions and current symptoms...
  39. ncbi request reprint Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab
    Konstantinos A Papadakis
    Division of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center, 8631 W Third Street, Suite 430E, Los Angeles, CA 90048, USA
    Am J Gastroenterol 100:75-9. 2005
    ..The aim of our study was to examine the safety and efficacy of adalimumab (D2E7), a fully humanized anti-TNF-alpha Ab, in CD patients who had experienced an attenuated response to infliximab...
  40. ncbi request reprint Determination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBD
    Shane M Devlin
    Inflammatory Bowel Disease Center, The University of Calgary, Calgary, Alberta, Canada
    Inflamm Bowel Dis 14:125-8; discussion 132-3. 2008
  41. ncbi request reprint Severe colitis in children
    Subra Kugathasan
    Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
    J Pediatr Gastroenterol Nutr 41:375-85. 2005
  42. pmc Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression
    Marla C Dubinsky
    Department of Pediatrics, Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Am J Gastroenterol 101:360-7. 2006
    ..We examined the association of immune responses to microbial antigens with disease behavior and prospectively determined the influence of immune reactivity on disease progression in pediatric CD patients...
  43. ncbi request reprint A pilot study of adalimumab in infliximab-allergic patients
    Adrienne Youdim
    Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA
    Inflamm Bowel Dis 10:333-8. 2004
    ..Based on these preliminary data, adalimumab may be a safe and effective substitute for infliximab-allergic patients. Individuals who have been exposed to human antibodies may be sensitized to other human antibodies such as adalimumab...

Research Grants4

  1. The Natural History of Pediatric Crohn's Disease
    Marla Dubinsky; Fiscal Year: 2007
    ..abstract_text> ..
  2. Parental Expression of Immune Responses In Pediatric Crohn's Disease
    Marla Dubinsky; Fiscal Year: 2007
    ..The characterization of the potential risk milieu implied by the presence of immune responses at the sub clinical level in the child's' parents will offer new information on the influence of immune phenotypes on clinical outcomes. ..